Literature DB >> 11384562

Immune Reconstitution Strategies in HIV.

Matthew R. Leibowitz1, Ronald T. Mitsuyasu.   

Abstract

Although potent antiretroviral therapy can dramatically decrease HIV replication and improve some aspects of host immunity, incomplete immune reconstitution persists even after several years of fully suppressive therapy. In addition, long-term toxicities of antiretroviral medications and the probability of developing multidrug-resistant virus with long-term use indicate that alternate means of controlling viral replication are needed for more durable suppression of HIV. Immune-based therapies may help potentiate the host's own defenses against HIV and other pathogens, and may ultimately result in more durable viral suppression and lower incidence of antiretroviral therapy-related side effects and toxicities.

Entities:  

Year:  2001        PMID: 11384562     DOI: 10.1007/s11908-001-0034-3

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  59 in total

Review 1.  Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection.

Authors:  J A Kovacs; H Masur
Journal:  N Engl J Med       Date:  2000-05-11       Impact factor: 91.245

2.  Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression.

Authors:  J A Kovacs; H Imamichi; S Vogel; J A Metcalf; R L Dewar; M Baseler; R Stevens; J Adelsberger; L Lambert; R T Davey; R E Walker; J Falloon; M A Polis; H Masur; H C Lane
Journal:  J Infect Dis       Date:  2000-09-05       Impact factor: 5.226

3.  Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation.

Authors:  N G Pakker; D W Notermans; R J de Boer; M T Roos; F de Wolf; A Hill; J M Leonard; S A Danner; F Miedema; P T Schellekens
Journal:  Nat Med       Date:  1998-02       Impact factor: 53.440

4.  Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. Leukine/HIV Study Group.

Authors:  J B Angel; K High; F Rhame; D Brand; J B Whitmore; J M Agosti; M J Gilbert; S Deresinski
Journal:  AIDS       Date:  2000-03-10       Impact factor: 4.177

5.  Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis.

Authors:  S M Whitcup; E Fortin; A S Lindblad; P Griffiths; J A Metcalf; M R Robinson; J Manischewitz; B Baird; C Perry; I M Kidd; T Vrabec; R T Davey; J Falloon; R E Walker; J A Kovacs; H C Lane; R B Nussenblatt; J Smith; H Masur; M A Polis
Journal:  JAMA       Date:  1999-11-03       Impact factor: 56.272

6.  Synergistic action of stem-cell factor and interleukin-7 in a human immature T-cell line.

Authors:  U R Kees; J Ford
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

7.  AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

Authors:  B Ledergerber; M Egger; V Erard; R Weber; B Hirschel; H Furrer; M Battegay; P Vernazza; E Bernasconi; M Opravil; D Kaufmann; P Sudre; P Francioli; A Telenti
Journal:  JAMA       Date:  1999-12-15       Impact factor: 56.272

8.  Changes in thymic function with age and during the treatment of HIV infection.

Authors:  D C Douek; R D McFarland; P H Keiser; E A Gage; J M Massey; B F Haynes; M A Polis; A T Haase; M B Feinberg; J L Sullivan; B D Jamieson; J A Zack; L J Picker; R A Koup
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

9.  Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.

Authors:  M M Lederman; E Connick; A Landay; D R Kuritzkes; J Spritzler; M St Clair; B L Kotzin; L Fox; M H Chiozzi; J M Leonard; F Rousseau; M Wade; J D Roe; A Martinez; H Kessler
Journal:  J Infect Dis       Date:  1998-07       Impact factor: 5.226

Review 10.  A primer on HIV type 1-specific immune function and REMUNE.

Authors:  R B Moss; W K Giermakowska; J R Savary; G Theofan; A E Daigle; S P Richieri; F C Jensen; D J Carlo
Journal:  AIDS Res Hum Retroviruses       Date:  1998-06       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.